Performance
Stock factor profile
BROOKS LABS
BROOKS · Healthcare · Pharmaceuticals & Biotechnology
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The firm has manufacturing plants at Baddi, Himachal Pradesh. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
Equity review factors
Factor profile
Factor scores are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags and screen results for BROOKS LABS are part of the Wright portfolio review.
Run your free portfolio reviewFundamental snapshot
Fundamentals at a glance
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.